Adhesion formation can be reduced by the suppression of transforming growth factor‐β1 activity

Abstract

Surgery or trauma often results in restrictive adhesions around joints or tendons that cause severe functional impairment. The formation of adhesion is essentially a fibrogenetic process; therefore, peptide growth factors, such as transforming growth factor-beta, are assumed to play central roles in its development. The purpose of this study was to test the hypothesis that suppression of transforming growth factor-beta1 activity reduces adhesion formation. Sixty rabbits were prepared and randomly divided into six groups of 10. Intraarticular adhesions were created in the right knee joints by cortical bone shaving and subsequent cast immobilization for 4 weeks. In animals in three of the six groups, transforming growth factor-beta1 activity was suppressed by continuous administration of the neutralizing antibody in three graded doses; animals in the other three groups were used as controls. Four weeks after the surgery, the casts were removed and the adhesions were assessed macroscopically, histologically, biomechanically, and biochemically. Gross observation showed that the neutralizing antibody had suppressed adhesion formation in a dose-dependent manner. This is consistent with biomechanical measurement results demonstrating that the antibody reduced the flexion contractures. Histologically, the adhesion in our model was fibrous tissue and the adhesions in the animals in the antibody groups were thin and loose in comparison with the controls. Biochemical analyses further supported these results, demonstrating that administration of the antibody reduced collagen content in the adhesions with a predominance of type-I collagen. Thus, this study showed that suppression of the actions of transforming growth factor-beta1 reduced adhesion formation. Considering the various possible measures to control the activity of the growth factor, suppression of transforming growth factor-beta may be a novel, potent approach to preventing adhesions.

All-trans retinoic acid prevents epidural fibrosis through NF-κB signaling pathway in post-laminectomy rats

“…Approximately 5 mg wet weight scar tissue was obtained from the surgical area. The HPC was examined as previously described (Fukui et al, 2000). The samples were lyophilized, ground and hydrolyzed with 6 mol/l HCl at 110 C for 24 h. Then 1 ml hydroxyproline developer (bedimethylaminobenzaldehyde solution) was added to the samples and standards.…”

RNA Interference Targeting Hypoxia Inducible Factor 1α Reduces Post-Operative Adhesions in Rats

“…Efforts to prevent adhesion formation have concentrated on inhibiting the inflammatory response, inhibiting the formation or encouraging the lysis of fibrin, and protection of the damaged organ surfaces [5]. Molecular therapeutics that have been investigated for the prevention of post-operative adhesions include recombinant tissue plasminogen activator (tPA) [7][8][9] and antibodies against PAI-1 [10], transforming growth factor ␤1 (TGF-␤1) [11,12], and vascular endothelial growth factor (VEGF) [13].…”

An FDA Approved Neurokinin-1 Receptor Antagonist is Effective in Reducing Intraabdominal Adhesions when Administered Intraperitoneally, But Not Orally

“…14,35,36 Overproduction of TGF-β, a multifunctional growth factor, correlates with adhesion formation in both humans and animals, [37][38][39] and in animal models, blocking TGF-β activity has been shown to reduce adhesion formation. 40,41 In support of a possible link between aprepitant and COX-2 and/or TGF-β, the NK-1R ligand substance P has been shown to upregulate COX-2 expression in cultured human umbilical vein endothelial cells and colonic epithelial cells, 42,43 and Figure 3 Twenty-four-hour postoperative rats showed a 233% greater PAI-1 mRNA level than vehicle controls (DMSO; N=3 per group). tPA mRNA levels were not statistically changed by aprepitant administration.…”